A Patient-centric Approach in the Harmony Phase 1/2 Trial of ADP101 for Food Allergies: Incorporating the Patient Voice

被引：0
|
作者：
Piscia-Nichols, Cheri [1 ]
Levin-Young, Olga [1 ]
Kirchner, Jim [1 ]
Sullivan, Amy [1 ]
机构：
[1] Alladapt Immunotherapeut, Menlo Pk, CA USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2024年 / 153卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
371
引用
收藏
页码：AB120 / AB120
页数：1
相关论文
共 41 条
  • [21] Multicenter phase trial of out-patient therapy with sequential low-dose interferon-γ-1b and interleukin-2 in advanced renal cell carcinoma
    Djavanmard, MP
    Kramer, G
    Steger, GG
    Zielinski, C
    Marberger, M
    JOURNAL OF UROLOGY, 1998, 159 (05): : 197 - 197
  • [22] 2:1 NURSE-PATIENT RATIO OUTSIDE PACU PHASE I: IMPLEMENTING A RN TANDEM APPROACH IN CARING FOR PREOP/PREANESTHESIA PATIENTS IN AN AMBULATORY PROCEDURE/SURGERY UNIT
    Libid, McRomeo
    Collins, Jenn
    Feldmann, Erica
    Reyes, Nolan
    Forsythe, Lori
    Kennedy, Michelle
    Hua, Krista
    Krick, Jennifer
    Ruiz, Lilia
    Hayes, Demetria
    Yee, Helen
    JOURNAL OF PERIANESTHESIA NURSING, 2018, 33 (04) : E20 - E20
  • [23] A LONGITUDINAL INVESTIGATION OF THE RELATIONSHIPS BETWEEN PATIENT REPORTED SYMPTOMS AND SURVIVAL AMONG PATIENTS WITH HR+/HER2-METASTATIC BREAST CANCER (MBC) TREATED WITH ABEMACICLIB IN THE PHASE 2 MONARCH 1 TRIAL
    Houghton, K.
    Boye, M. E.
    Price, G. L.
    Stull, D. E.
    Tolaney, S. M.
    VALUE IN HEALTH, 2017, 20 (09) : A413 - A413
  • [24] Patient-centered initiatives for improving trial participation of diverse patient populations in the open-label phase 3b compLEEment-1 study of ribociclib plus letrozole in the treatment of HR+/HER2-advanced breast cancer
    Small, Tania
    Marsano-Feeley, Jaclyn
    Fernandez, Alberto
    Grasso, Tina
    Feldman, Katherine
    Petrone, Stephanie
    Bugazia, Najla
    Wong, Celena
    Meyer, Julie
    Schutta, Katie
    Purkayastha, Das
    Saintil, Krystal
    Caplan, Elyse Spatz
    Waltman-Johnson, Katherine
    CANCER RESEARCH, 2018, 78 (04)
  • [25] Patient Reported Outcomes (PRO) From Ongoing Phase 2 Registrational Trial of Repotrectinib in Patients With ROS1-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (TRIDENT-1)
    Shim, A.
    Trone, D.
    Reynolds, M.
    Odom, D.
    Sherif, B.
    Stopatschinskaja, S.
    VALUE IN HEALTH, 2022, 25 (12) : S421 - S421
  • [26] Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial
    Fasching, P. A.
    Quek, R. G. W.
    Bhattacharyya, H.
    Hurvitz, S. A.
    Rugo, H. S.
    Ettl, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [27] Single-Institution Phase 1/2 Prospective Trial Evaluating Three-Fraction Partial Breast Irradiation: Four Year Outcomes Including Quantitative Cosmesis and Patient-Reported Outcomes
    Raju, S. C.
    Mahmood, M.
    Zoberi, J. E.
    Thomas, M. A.
    Ochoa, L. L.
    Garcia-Ramirez, J. L.
    Zoberi, I.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : S83 - S83
  • [28] Etrasimod, a novel, oral selective S1P receptor modulator, in adults with moderate-to-severe atopic dermatitis: Analysis of patient-reported outcomes and itch in a phase 2 trial
    Murrell, D. F.
    Guttman-Yassky, E.
    Bissonnette, R.
    Kircik, L.
    Selfridge, A.
    Liu, K.
    Ahluwalia, G.
    Silverberg, J. I.
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 18 - 19
  • [29] Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial
    Hurvitz, S. A.
    Quek, R. G. W.
    Turner, N. C.
    Telli, M. L.
    Rugo, H. S.
    Mailliez, A.
    Ettl, J.
    Grischke, E.
    Mina, L. A.
    Balmana, J.
    Fasching, P. A.
    Bhattacharyya, H.
    Hannah, A. L.
    Robson, M. E.
    Wardley, A. M.
    EUROPEAN JOURNAL OF CANCER, 2018, 104 : 160 - 168
  • [30] Final results of the phase I trial of niraparib (MK4827), a poly (ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutation carriers, sporadic ovarian, and castration resistant prostate cancer (CRPC).
    Michie, Caroline Ogilvie
    Sandhu, Shahneen Kaur
    Schelman, William R.
    Molife, L. Rhoda
    Wilding, George
    Omlin, Aurelius Gabriel
    Kansra, Vikram
    Brooks, David G.
    Martell, Robert E.
    Kaye, Stanley B.
    De Bono, Johann Sebastian
    Wenham, Robert Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345